Systemic Scleroderma Treatment Market

Systemic Scleroderma Treatment Market by Drugs Class (Immunosuppressors, Phosphodiesterase 5 inhibitors - PHA, Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers, and Others) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-1944
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 2
  • No. Of Pages: 170
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global systemic scleroderma treatment market size was valued at USD 1.42 billion in 2020 and is projected to reach USD 2.03 billion by 2028, expanding at a CAGR of 3.9% during the forecast period, 2021–2028. The growth of the market is attributed to the supplemental approvals for preexisting treatment option, as well as the emergence of first-in-class treatments.

Systemic Scleroderma Treatment Market Key Takeaways

Scleroderma is a skin disorder, which is the result of frequent accumulation of scar tissue or fibrosis on the skin and other organs. Fibrosis, as a condition of overproducing a protein called collagen, can not only affect the skin but also other organs without a proper treatment. The condition can damage several internal organs such as kidneys, heart, and lungs due to malfunctioning effects. Researchers and sponsors are focusing their efforts to develop new prospective treatment and innovative methods of their pipeline products. For example, Kadmon Holdings, Inc. finalized its acquisition of Orphan Medication Designation in September 2020 and got approved from the US Food and Drug Administration for its innovative drug candidate, belumosudil (KD025), which is designed to treat systemic sclerosis. Belumosudil (KD025) is a Rho-associated coiled-coil kinase 2 inhibitor that offer a dual mode of action to target both immunological and fibrotic components. It is currently being tested in a phase 2 clinical trial.

The failure of a recent clinical trial adds to the difficulty of developing treatments for this disease. For example, despite promising phase 2 clinical trial findings, Corbus Pharmaceuticals Holdings Inc.'s pipeline candidate Lenabasum failed to show benefits across the primary and secondary endpoints in September 2020. The participation of a wide range of pharmacological classes administered in first-, second-, and third-line therapy of the condition is due to comorbidities associated with this disease.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing off-label use of drugs approved for its symptomatic indications such as rheumatoid arthritis is estimated to drive the market during the forecast period.
  • Introduction of targeted biologics and small molecule combination treatments for rare illness and development of curative medicines are projected to boost the market growth.
  • The absence of validated outcome metrics and rising failures cases of previous treatment pose unique hurdles in the drug development. This is expected to impede the market expansion.
  • Successful commercialization of various medication classes and branded medications available for the treatment of this skin disorder present lucrative opportunities for the market expansion.

Scope of the Report

The report on the global systemic scleroderma treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Systemic Scleroderma Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Drugs Class (Immunosuppressors, Phosphodiesterase 5 inhibitors - PHA, Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

F. Hoffmann La Roche Ltd.; Johnson & Johnson Services, Inc.; United Therapeutics; Boehringer Ingelheim International GmbH; GlaxoSmithKline plc; Pfizer, Inc.; Eli Lilly and Company; Bayer AG; Mylan N.V.; and Teva Pharmaceutical Industries Ltd.

Market Segment Insights

Phosphodiesterase 5 inhibitors - PHA segment to account for a key market share

Based on drugs class, the systemic scleroderma treatment market is segmented into immunosuppressors, phosphodiesterase 5 inhibitors - PHA, endothelin receptor antagonists, prostacyclin analogues, calcium channel blockers, and others. The phosphodiesterase 5 inhibitors segment is expected to hold a key share of the market during the forecast period. Several pharmaceutical companies are focusing on label expansion in order to broaden their customer base. Pfizer Inc., for example, announced the completion of clinical trials studies for Revatio for the treatment of pulmonary hypertension in newborns in June 2020.

Meanwhile, the immunosuppressors segment dominated the market, accounting for over 64.5% of the total revenue of the market in 2020 as a wide range of pharmacological classes are administered to alleviate symptoms. Immunosuppressants are the most common drug types as this category includes multiple biologics developed by several players. A developing category includes biologics and small molecule immunosuppressors, with numerous pipeline medicines for systemic scleroderma focused on this class.

Systemic Scleroderma Treatment Market By Drugs Class

Europe is anticipated to dominate the market

On the basis of regions, the systemic scleroderma treatment market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Europe is anticipated to dominate the market expanding at an impressive CAGR during the forecast period. The regional market growth can be attributed to the introduction of biologics and small molecules for the treatment of systemic sclerosis and its associated indications. Moreover, the rapid introduction of biologics and small molecules for the treatment of systemic sclerosis and its associated indications especially in the UK present a dynamic aspect for the segment growth. Uptravi was approved by the European Medicines Agency (EMA) in May 2016, according to Actelion Pharmaceuticals Ltd., a subsidiary of Johnson and Johnson Services, Inc.

Meanwhile, North America dominated the market in 2019, accounting for more than 40.2% of the total revenue share and is estimated to hold a key share of the market in the coming years. The key revenue driver of the region is due to rapid access to recently developed immunosuppressants combined with a favorable reimbursement scenario of the disease treatment. In the US, there are around 276 cases of systemic sclerosis per million people and around 20 instances of systemic scleroderma per million individuals. Furthermore, the total direct healthcare cost per patient was estimated to be between USD 17,365 and USD 18,396. The growing market for systemic scleroderma treatment is fueled by the disease's consistent burden. In comparison to North America, Europe has a lower share, owing to the increased usage of generics and biosimilars for off-label therapy of systemic scleroderma.

Systemic Scleroderma Treatment Market By Regions

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Systemic Scleroderma Treatment Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Systemic Scleroderma Treatment Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Systemic Scleroderma Treatment Market - Supply Chain
  4.5. Global Systemic Scleroderma Treatment Market Forecast
     4.5.1. Systemic Scleroderma Treatment Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Systemic Scleroderma Treatment Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Systemic Scleroderma Treatment Market Absolute $ Opportunity
5. Global Systemic Scleroderma Treatment Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Systemic Scleroderma Treatment Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Systemic Scleroderma Treatment Demand Share Forecast, 2019-2026
6. North America Systemic Scleroderma Treatment Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Systemic Scleroderma Treatment Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Systemic Scleroderma Treatment Demand Share Forecast, 2019-2026
7. Latin America Systemic Scleroderma Treatment Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Systemic Scleroderma Treatment Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Systemic Scleroderma Treatment Demand Share Forecast, 2019-2026
8. Europe Systemic Scleroderma Treatment Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Systemic Scleroderma Treatment Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Systemic Scleroderma Treatment Demand Share Forecast, 2019-2026
9. Asia Pacific Systemic Scleroderma Treatment Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Systemic Scleroderma Treatment Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Systemic Scleroderma Treatment Demand Share Forecast, 2019-2026
10. Middle East & Africa Systemic Scleroderma Treatment Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Systemic Scleroderma Treatment Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Systemic Scleroderma Treatment Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Systemic Scleroderma Treatment Market: Market Share Analysis
  11.2. Systemic Scleroderma Treatment Distributors and Customers
  11.3. Systemic Scleroderma Treatment Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. F. Hoffmann La Roche Ltd. Johnson & Johnson Services, Inc. United Therapeutics Boehringer Ingelheim International GmbH GlaxoSmithKline plc Pfizer, Inc.  
Segments Covered in the Report
The global systemic scleroderma treatment market has been segmented on the basis of

Drugs Class
  • Immunosuppressors
  • Phosphodiesterase 5 inhibitors - PHA
  • Endothelin Receptor Antagonists
  • Prostacyclin Analogues
  • Calcium Channel Blockers
  • Others
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • F. Hoffmann La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • United Therapeutics
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc
  • Pfizer, Inc.
  • Eli Lilly and Company
  • Bayer AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.

Key players competing in the systemic scleroderma treatment market are F. Hoffmann La Roche Ltd.; Johnson & Johnson Services, Inc.; United Therapeutics; Boehringer Ingelheim International GmbH; GlaxoSmithKline plc; Pfizer, Inc.; Eli Lilly and Company; Bayer AG; Mylan N.V.; and Teva Pharmaceutical Industries Ltd. The market for systemic scleroderma treatment has a lot of room for expansion and a lot of unmet medical needs. Mergers and acquisitions, as well as partnerships, are being used by pharmaceutical corporations to gain a greater global market share. Janssen Pharmaceutical, a division of Johnson & Johnson Services, Inc., completed the acquisition of Actelion Pharmaceuticals Ltd. in 2017, making it the leading player in the pulmonary hypertension market. Due to the increased penetration of this class of medications and their superior efficacy over existing options such as cyclophosphamide, methotrexate, and mycophenolate mofetil, these therapies are expected to reign until the arrival of curatives in clinical trials.

The FDA approved Boehringer Ingelheim International GmbH's medication, Ofev (nintedanib), for the treatment of patients with Systemic Sclerosis with Interstitial Lung Disease (SSc-ILD) in September 2019, followed by the European Medicines Agency (EMA) in April 2020. In addition, newer medicines such as nilotinib and ziritaxestat are likely to join the market over the projected period, which is categorized as "other drug classes."

Systemic Scleroderma Treatment Market By Key Players

Buy Report